Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918

This article has now been updated. Please use the final version.

Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib: A Case Report
Hiroyuki AraiShinya YamamotoTakeshi MatsubaraTakafumi MiyakeAkira TochioAkiko MiiAkira ShimizuSachiko MinamiguchiEri MusoMotoko Yanagita
Author information
JOURNAL OPEN ACCESS Advance online publication

Article ID: 1283-22

Details
Abstract

Ponatinib is a novel multi-tyrosine kinase inhibitor (TKI) with potent inhibitory activity against refractory chronic myeloid leukemia (CML). Despite its high clinical efficacy, ponatinib induces various adverse events due to its multi-target characteristic. However, renal complications associated with ponatinib are rare. A 76-year-old woman had a history of chronic myeloid leukemia (CML) resistant to imatinib and nilotinib. Our patient developed proteinuria and renal function deterioration during treatment with ponatinib but not with imatinib or nilotinib. We herein report the first case of a patient with secondary focal segmental glomerulosclerosis (FSGS) with partial glomerular collapse induced by ponatinib treatment.

Content from these authors
© 2023 by The Japanese Society of Internal Medicine
feedback
Top